Comparative effectiveness research in localized prostate cancer treatment

Journal of Comparative Effectiveness Research

Volumn 2, Issue 6, 2013, Pages 583-593

  Hoffman, Richard M ^a,b   Penson, David F ^c,d   Zietman, Anthony L ^e,f   Barry, Michael J ^e,g  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g Informed Medical Decisions Foundation   (United States)

Author keywords

cohort studies; comparative effectiveness research; decision support techniques; decision making; prostatectomy; prostatic neoplasms; quality of life; radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COMPARATIVE EFFECTIVENESS; DISEASE SURVEILLANCE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LAPAROSCOPIC SURGERY; MEDICARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; ROBOTICS; SIMULATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; ULTRASOUND THERAPY; WATCHFUL WAITING;

COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; MALE; OBSERVATIONAL STUDY AS TOPIC; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84887220439     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.13.66     Document Type: Review

References (72)

1. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specifc antigen screening: 1986-2005. J. Natl Cancer Inst. 101(19), 1325-1329 (2009).
2. Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specifc antigen screening: importance of methods and context. J. Natl Cancer Inst. 101(6), 374-383 (2009).
3. Harlan LC, Potosky A, Gilliland FD et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J. Natl Cancer Inst. 93(24), 1864-1871 (2001). (Pubitemid 34048653)
4. Schymura MJ, Kahn AR, German RR et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 10, 152 (2010).
5. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28 (7), 1117-1123 (2010).
6. Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177(6), 2106-2131 (2007). (Pubitemid 46726449)
7. Ganz PA, Barry JM, Burke W et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann. Intern. Med. 156(8), 591-595 (2012).
8. Penson DF, Rossignol M, Sartor AO, Scardino P T, Abenhaim LL. Prostate cancer: epidemiology and health-related quality of life. Urology 72(6 Suppl.), S3-S11 (2008).
9. Fransson P, Damber JE, Tomic R, Modig H, Nyberg G, Widmark A. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer 92(12), 3111-3119 (2001). (Pubitemid 33136207)
10. Resnick MJ, Koyama T, Fan KH et al. Long-term functional outcomes after treatment for localized prostate cancer. N. Engl. J. Med. 368(5), 436-445 (2013).
11. Johansson E, Steineck G, Holmberg L et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 12(9), 891-899 (2011).
12. Zeliadt SB, Ramsey SD, Penson DF et al. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 106(9), 1865-1874 (2006). (Pubitemid 43673200)
13. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283(24), 3217-3222 (2000). (Pubitemid 30422039)
14. Kramer KM, Bennett CL, Pickard AS et al. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin. Prostate Cancer 4(1), 15-23 (2005). (Pubitemid 41018178)
15. Crook JM, Gomez-Iturriaga A, Wallace K et al. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J. Clin. Oncol. 29(4), 362-368 (2011).
16. Donovan J, Hamdy F, Neal D et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol. Assess. 7(14), 1-88 (2003).
17. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand. J. Urol. Nephrol. Suppl. 172, 65-72 (1995).
18. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med. 347(11), 781-789 (2002). (Pubitemid 34988336)
19. Bill-Axelson A, Holmberg L, Filen F et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J. Natl Cancer Inst. 100(16), 1144-1154 (2008).
20. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 364(18), 1708-1717 (2011).
21. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352(19), 1977-1984 (2005). (Pubitemid 40638368)
22. Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367(3), 203-213 (2012).
23. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA 296(19), 2336-2342 (2006). (Pubitemid 44749361)
24. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specifc antigen test among US men: fndings from the 2005 National Health Interview Survey. Cancer Epidemiol. Biomarkers Prev. 17(3), 636-644 (2008). (Pubitemid 351469214)
25. Hoffman RM, Hunt WC, Gilliland FD et al. Satisfaction with treatment decisions for clinically localized prostate cancer. Results from the Prostate Cancer Outcomes Study. Cancer 97, 1653-1662 (2003). (Pubitemid 36350709)
26. Chodak G, Gomella L, Phung de H. Combined androgen blockade in advanced prostate cancer: looking back to move forward. Clin. Genitourin. Cancer 5(6), 371-378 (2007). (Pubitemid 47584474)
27. Jones CU, Hunt D, McGowan DG et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 365(2), 107-118 (2011).
28. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299(3), 289-295 (2008). (Pubitemid 351159365)
29. Lu-Yao GL, Albertsen PC, Moore DF et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300(2), 173-181 (2008). (Pubitemid 351969301)
30. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28(1), 126-131 (2010).
31. Tosoian JJ, Trock BJ, Landis P et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J. Clin. Oncol. 29(16), 2185-2190 (2011).
32. Cooperberg MR, Cowan JE, Hilton JF et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J. Clin. Oncol. 29(2), 228-234 (2011).
33. Bul M, Zhu X, Valdagni R et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur. Urol. 63(4), 597-603 (2013).
34. Walsh PC, Epstein JI, Lowe FC. Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J. Urol. 138(4), 823-827 (1987). (Pubitemid 17150770)
35. Barbash GI, Glied SA. New technology and health care costs-the case of robot assisted surger y. N. Engl. J. Med. 363 (8), 710-704 (2010).
36. Schroeck FR, Krupski TL, Sun L et al. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur. Urol. 54(4), 785-793 (2008).
37. Barry MJ, Gallagher PM, Skinner JS, Fowler FJ Jr. Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of Medicare-age men. J. Clin. Oncol. 30(5), 513-518 (2012).
38. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol. 21(21), 3972-3978 (2003). (Pubitemid 46606211)
39. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised Phase III trial. Lancet 373(9660), 301-308 (2009).
40. Roach III M, Thomas K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States Preventative Task Force report on screening? J. Natl Cancer Inst. Monogr. 45, 221-229 (2013).
41. Oyesanmi O, Sun F, Fontanarosa J, Bekelman J, Guzzo T, Schoelles K. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer: An Update of the 2008 Report. Agency for Health Care Research and Quality, MD, USA (2013).
42. Bannuru RR, Dvorak T, Obadan N et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Ann. Intern. Med. 155, 171-178 (2011).
43. Hu JC, Gu X, Lipsitz SR et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302(14), 1557-1564 (2009).
44. Potosky AL, Harlan LC, Stanford JL et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J. Natl Cancer Inst. 91(20), 1719-1724 (1999). (Pubitemid 29518766)
45. Lubeck DP, Litwin MS, Henning JM et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48(5), 773-777 (1996). (Pubitemid 26398700)
46. Barocas DA, Chen V, Cooperberg M et al. Using a population-based observational cohort study to address diffcult comparative effectiveness research questions: the CEASAR study. J. Comp. Eff. Res. 2(4), 445-460 (2013).
47. Potosky AL, Davis W W, Hoffman RM et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J. Natl Cancer Inst. 96(18), 1358-1367 (2004). (Pubitemid 39406169)
48. Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study. Am. J. Med. 119(5), 418-425 (2006).
49. Potosky AL, Reeve BB, Clegg LX et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J. Natl Cancer Inst. 94(6), 430-437 (2002). (Pubitemid 34285092)
50. Hoffman RM, Koyama T, Fan KH et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J. Natl Cancer Inst. 105(10), 711-718 (2013).
51. Daskivich TJ, Fan KH, Koyama T et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer. Ann. Intern. Med. 158(10), 709-717 (2013).
52. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116(22), 5226-5234 (2010).
53. Litwin MS, Greenfeld S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer 109(9), 1777-1783 (2007). (Pubitemid 46668540)
54. Wong YN, Mitra N, Hudes G et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296(22), 2683-2693 (2006). (Pubitemid 44917546)
55. Lu-Yao GL, Barry MJ, Albertsen PC, Yao SL. Outcomes of treatment vs observation of localized prostate cancer in elderly men. JAMA 297(15), 1651; author reply 1652-1653 (2007). (Pubitemid 46631632)
56. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. 127(8 Pt 2), 757-763 (1997). (Pubitemid 27446562)
57. Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J. Natl Cancer Inst. 102(23), 1780-1793 (2010).
58. Schroder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 366 (11), 981-990 (2012).
59. Andriole GL, Crawford ED, Grubb RL, 3rd et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J. Natl Cancer Inst. 104(2), 125-132 (2012).
60. Heijnsdijk EA, Wever EM, Auvinen A et al. Quality-of-life effects of prostate-specifc antigen screening. N. Engl. J. Med. 367(7), 595-605 (2012).
61. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the true number needed to screen and treat to save a life with prostate-specifc antigen testing? J. Clin. Oncol. 29(4), 464-467 (2011).
62. Gulati R, Wever EM, Tsodikov A et al. What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol. Biomarkers Prev. 20(5), 740-750 (2011).
63. Hayes JH, Ollendorf DA, Pearson SD et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision ana lysis. JAMA 304(21), 2373-2380 (2010).
64. Hayes JH, Ollendorf DA, Pearson SD et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann. Intern. Med. 158(12), 853-860 (2013).
65. Denberg TD, Melhado TV, Steiner JF. Patient treatment preferences in localized prostate carcinoma: the infuence of emotion, misconception, and anecdote. Cancer 107(3), 620-630 (2006). (Pubitemid 44107224)
66. Stacey D, Bennett CL, Barry MJ et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev. 10, CD001431 (2011).
67. Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J. Clin. 59(6), 379-390 (2009).
68. Hoffman RM. Improving the communication of benefts and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions. J. Natl Cancer Inst. Monogr. 2012(45), 197-201 (2012).
69. Zietman A, Goitein M, Tepper JE. Technology evolution: is it survival of the fttest? J. Clin. Oncol. 28(27), 4275-4279 (2010).
70. Abdollah F, Sun M, Schmitges J et al. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study. Int. J. Radiat. Oncol. Biol. Phys. 84(1), 95-103 (2012).
71. Abdollah F, Schmitges J, Sun M et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int. J. Urol. 19(9), 836-844; author reply 844-835 (2012).
72. Sheets NC, Goldin GH, Meyer AM et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307(15), 1611-1620 (2012).